GlassScriptPhysician profile
Laura R Petty
NPI 1134431414
$2,560.08
in general payments reported to CMS, 2019-2025
33 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $315 · 2021: $659 · 2022: $319 · 2023: $307 · 2024: $350 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.02 | 2019-2023 | |
| Aspira Women'S Health INC | $315.73 | 2021 | |
| Lupin INC. | $314.58 | 2019-2021 | |
| Pfizer INC. | $285.78 | 2019-2024 | |
| Astellas Pharma US INC | $185.46 | 2022-2024 | Veozah |
| Evofem Biosciences, INC. | $183.30 | 2021-2022 | |
| Hologic Sales and Service, LLC | $93.83 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Omni Hysteroscope |
| Mayne Pharma Commercial LLC | $81.15 | 2023-2024 | |
| Intuitive Surgical, INC. | $58.16 | 2019 | |
| Dexcom, INC. | $53.43 | 2025 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $49.48 | 2019-2021 | |
| Roche Diagnostics Corporation | $45.53 | 2019 | |
| Avion Pharmaceuticals | $45.03 | 2020-2023 | Balcoltra |
| Exeltis, USA INC. | $44.97 | 2024 | Slynd |
| Amgen INC. | $40.60 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $38.76 | 2019-2020 | |
| Lilly USA, LLC | $38.58 | 2024-2025 | Zepbound |
| Amag Pharmaceuticals, INC. | $33.79 | 2019 | |
| Ethicon US, LLC | $33.28 | 2020 | |
| Smith+Nephew, INC. | $31.55 | 2024 | Pico 14, Renasys Touch, Pico 7 |
| Duchesnay USA Incorporated | $25.73 | 2019 | |
| Organon LLC | $25.06 | 2023 | Nexplanon |
| Novo Nordisk INC | $24.87 | 2023 | Wegovy |
| Biogen, INC. | $22.98 | 2024 | Spinraza |
| Sumitomo Pharma America, INC. | $21.05 | 2024 | Myfembree |
| Minerva Surgical, INC | $20.04 | 2022 | |
| Daiichi Sankyo INC. | $19.31 | 2021 | |
| Medicem INC. | $17.04 | 2022 | |
| Axonics, INC. | $16.97 | 2022 | |
| Exact Sciences Corporation | $16.27 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $16.05 | 2021 | |
| Sage Therapeutics, LLC | $12.75 | 2022 | |
| Merck Sharp & Dohme LLC | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Petty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.